Wolfgang Miesbach: Direct Comparison Reveals Distinct Mechanisms Among FVIIIa Mimetics
Wolfgang Miesbach, Head of Hemostasis/Hemophilia Center at Medical Clinic 2 at University Hospital Frankfurt, shared a post on LinkedIn about a recent article by Jacob Lund et al, published in Journal of Thrombosis and Haemostasis, adding:
“Three FVIIIa mimetics, one assay system: finally comparable. FVIIIa mimetics are bispecific antibodies that stand in for factor VIII by holding FIXa and FX together so that FX can be activated. Emicizumab, denecimig (Mim8) and zemocimig (NXT007) all work this way, but their published data came from different labs, assays and reagent lots. Lund et al. have now tested all three under identical conditions (RPTH).
Binding: zemocimig holds the FIXa/FX complex most tightly (KD 0.31 nM), emicizumab intermediate (1.06 nM), denecimig only loosely (16.4 nM).
Turnover: denecimig compensates with >200-fold higher catalytic activity (29.6 vs 0.11–0.14 min⁻¹). It binds briefly, activates FX and lets go, then starts again.
Net effect: in thrombin generation in severe haemophilia A plasma, denecimig ≈ zemocimig, both clearly above emicizumab.
Two opposite design routes, hold tight or let go fast, arrive at the same haemostatic endpoint.
Worth keeping in mind: in vitro, company-sponsored, deliberately simplified system. More thrombin in a tube is not the same as better outcomes. Once generation reaches or exceeds the normal range, the questions become therapeutic window, thrombogenicity and dosing.
Congratulations to Jacob Lund and co-authors.”
Title: In vitro effects of combining Mim8 with factor VIII, FVIIa, and activated prothrombin complex concentrates in thrombin generation assays
Authors: Jacob Lund, Kasper Jensen, Laurent Burnier, Mirella Ezban

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 18, 2026, 01:45Shikha Jha: My Takeaways from the 4th GANSID International Congress
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support